Die Ema hat gestern übrigens nach der PEI Meldung nochmal ein update rausgehauen:
https://www.ema.europa.eu/en/news/emas-s...lic-events
Das klingt jetzt aber schon anders als letzte Woche wo es hieß:
Zitat:EMA currently remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects.
............EMA’s safety committee (PRAC) will further review the information tomorrow (Tuesday) and has called an extraordinary meeting on Thursday 18 March to conclude on the information gathered and any further actions that may need to be taken.
https://www.ema.europa.eu/en/news/emas-s...lic-events
Das klingt jetzt aber schon anders als letzte Woche wo es hieß:
Zitat:There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine. The position of EMA’s safety committee PRAC is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing. PRAC is already reviewing all cases of thromboembolic events, and other conditions related to blood clots, reported post-vaccination with COVID-19 Vaccine AstraZeneca.
The number of thromboembolic events in vaccinated people is no higher than the number seen in the general population. As of 10 March 2021, 30 cases1 of thromboembolic events had been reported among close to 5 million people vaccinated with COVID-19 Vaccine AstraZeneca in the European Economic Area.
EMA will further communicate as the assessment progresses.